Mode
Text Size
Log in / Sign up
N/A N=272 Randomized Triple-blind Treatment

Clinical Investigation of the Safety and Effectiveness of an Investigational Model of the TECNIS® Intraocular Lens

Cataract · Corneal Astigmatism

Enrolled (actual)
272
Serious AEs
3.5%
Results posted
Aug 2021
Primary outcome: Primary: Distance-Corrected Near Visual Acuity (DCNVA) at 40 cm — 0.104; 0.522 LogMAR — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
IOL Model ZFR00V (Device); IOL Model ZCB00 (Device)
Age
Adult, Older Adult · 22+ yrs
Sex
All
Sponsor
Johnson & Johnson Surgical Vision, Inc.
Primary completion
Jun 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Distance-Corrected Near Visual Acuity (DCNVA) at 40 cm
0.104; 0.522 <0.0001 sig
SECONDARY
Monocular Distance-Corrected Intermediate Visual Acuity at 66 cm
0.060; 0.335 <0.0001 sig
SECONDARY
Monocular Distance-Corrected Near Visual Acuity at 33 cm
0.154; 0.608 <0.0001 sig
SECONDARY
Monocular Photopic Best-Corrected Distance Visual Acuity
-0.014; -0.045
SECONDARY
Monocular Distance-Corrected Defocus Curve
-3.3; -0.9
SECONDARY
Spectacle Wear
115; 4; 16; 127; 0; 0 <0.0001 sig

Summary

This study will be a prospective, multicenter, bilateral, comparative, three-way masked (Sponsor, subject and evaluator), randomized clinical investigation conducted at up to 15 sites. Up to 300 subjects will be enrolled to achieve approximately 270 bilaterally implanted subjects, resulting in approximately 244 evaluable subjects (122 per lens group) at 6 months. After informed consent is obtained and confirmation that all eligibility criteria are met, the eye(s) may be treated according to randomization. After signing the informed consent form, subjects meeting all eligibility criteria will be randomized in a masked fashion to a treatment group: either the investigational IOL Model ZFR00V or the control IOL Model ZCB00. Prior to randomization, the investigator will choose which eye to operate on first for each subject at his/her discretion based on his/her standard clinical practice (e.g., the eye with the worse cataract, poorer best corrected distance vision and/or more severe optical/visual complaints). All subjects are intended to have bilateral cataract surgery with the second eye surgery occurring after the 1-week postoperative exam for the first eye, but no more than 30 days after the first eye surgery. All subjects will be examined through 6 months postoperatively according to the visit schedule

Eligibility Criteria

Inclusion Criteria

  • be at least 22 years old
  • have cataracts in both eyes
  • sign the written informed consent
  • be willing and able to comply with examination procedures
  • understand, read and write English to complete informed consent and questionnaires
  • be available for study follow-up visits

Exclusion Criteria

  • currently participating in any other clinical study or have participated in a clinical study during the last 60 days
  • have a certain disease/illness such as poorly-controlled diabetes
  • have certain ocular conditions such as uncontrolled glaucoma
  • Is taking medication that may affect vision
  • Subject is pregnant, plan to become pregnant during the study, or is breastfeeding
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03949335). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search